Table 3 Comparison of thyroid function and autoantibody indicators of the patients at 3 months of therapy
Characteristics of early therapy | Refractory (n = 172) | Non-refractory (n = 174) | P value |
|---|---|---|---|
fT3 (3 m)a (pmol/L) | 6.7 (5.0–9.7) | 6.2 (4.7–7.8) | 0.037 |
fT3 (3 m percentage decrease)b (%) | 69.7 ± 16.6 | 70.4 ± 15.7 | 0.421 |
fT3 (3 m accumulation)c (day*pmol/L) | 1046.4 (823.4–1394.6) | 998.1 (751.3–1299.1) | 0.126 |
fT4 (3 m)a (pmol/L) | 20.7 (15.2–26.4) | 18.6 (14.4–22.1) | 0.023 |
fT4 (3 m percentage decrease)b (%) | 68.6 ± 17.8 | 66.7 ± 16.2 | 0.435 |
fT4 (3 m accumulation)c (day*pmol/L) | 2710.6 (2019.6–3539.5) | 2770.3 (2077.2–3511.8) | 0.957 |
TSH (3 m)a (mIU/L) | 1.5 (0.3–4.8) | 1.9 (0.4–4.8) | 0.093 |
TSH (3 m percentage increase)b (%) | 29,472.0 (4117.1–89,921.0) | 36,701.0 (8772.7–102,865.7) | 0.157 |
TSH (3 m accumulation)c (day*mIU/L) | 79.4 (7.3–242.2) | 63.9 (5.4–208.4) | 0.441 |
TPOAb (3 m)a (IU/mL) | 137.1 (39.0–312.5) | 84.9 (25.6–201.8) | 0.015 |
TPOAb (3 m percentage decrease)b (%) | 19.1 (2.6–33.8) | 18.8 (11.4–36.0) | 0.994 |
TPOAb (3 m accumulation)c (day* IU/mL) | 15,056.7 (3600.4–29,545.1) | 8892.8 (1818.1–22,319.4) | 0.009 |
TgAb (3 m)a (IU/mL) | 230.1 (48.1–442.9) | 168.5 (19.5–436.7) | 0.048 |
TgAb (3 m percentage decrease)b (%) | 38.1 (0.6–58.6) | 21.7 (12.0–51.1) | 0.003 |
TgAb (3 m accumulation)c (day* IU/mL) | 23,858.0 (4768.6–44,855.1) | 19,148.7 (2914.0–45211.9) | 0.512 |
TRAb (3 m)a (IU/L) | 6.5 (2.8–12.5) | 4.7 (2.5–9.2) | 0.045 |
TRAb (3 m percentage decrease)b (%) | 44.8 (25.6–63.2) | 36.5 (56.5–17.1) | 0.019 |
TRAb (3 m accumulation)c (day* IU/L) | 1081.9 (425.5–1634.8) | 605.7 (316.7–1210.5) | < 0.001 |